Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00433641 · ClinicalTrials.gov registry record · Phase 4
Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 181
- Enrollment target
NCT00433641: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT00433641 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 181 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00433641, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 181 participants
- Enrollment target
Study Summary
Control of food intake, size and frequency of meals are critical to the development of obesity. The stomach signals feelings of fullness after a meal and therefore plays a role in control of calorie intake. It is unclear whether the approved appetite reducing drug sibutramine changes the function of the stomach. Differences in the way individuals respond to treatment with the appetite suppressant sibutramine may also explain why some people lose weight while others do not. In a previous study of 48 overweight or obese participants, we preliminarily observed that variation in the gene for the promoter of the serotonin transporter protein was significantly associated with degree of weight loss. This new single center clinical study aims to evaluate the effects of the FDA-approved appetite suppressing medication, sibutramine (MERIDIA)on weight loss and stomach emptying in patients who are overweight or obese. The effect of individual differences in inherited genes that modify serrotonin and noradrenergic receptors on weight reduction with sibutramine will be tested.
Interventions
- DRUG sibutramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00433641
The ClinicalTrials.gov registry entry for NCT00433641 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sibutramine is the first listed.
NCT00433641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00433641 about?
NCT00433641 is a clinical study titled "Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes". Control of food intake, size and frequency of meals are critical to the development of obesity. The stomach signals feelings of fullness after a meal and therefore plays a role in control of calorie intake. It is unclear whether the approved appetite reducing drug sibutramine changes the function of...
What is the current status of trial NCT00433641?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 181 participants. The study started on 2006-07. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00433641?
The interventions under investigation include: sibutramine (DRUG).
Who is sponsoring clinical trial NCT00433641?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.